1. Effect of nocturnal EPAP titration to abolish tidal expiratory flow limitation in COPD patients with chronic hypercapnia: a randomized, cross-over pilot study
- Author
-
Luca Barbano, Ilaria Milesi, Simona Cacciatore, Rossella Trentin, Roberto Porta, Emanuela Zannin, Michele Vitacca, Raffaele Dellaca, and Francesco Fanfulla
- Subjects
Male ,medicine.medical_specialty ,Copd patients ,Polysomnography ,Flow limitation ,Pilot Projects ,Nocturnal ,Hypercapnia ,Positive-Pressure Respiration ,Pulmonary Disease, Chronic Obstructive ,03 medical and health sciences ,Work of breathing ,0302 clinical medicine ,Internal medicine ,Tidal Volume ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Aged ,Oxygen saturation (medicine) ,Aged, 80 and over ,lcsh:RC705-779 ,COPD ,Cross-Over Studies ,Noninvasive Ventilation ,Pulmonary Gas Exchange ,business.industry ,Research ,Chronic obstructive pulmonary disease ,lcsh:Diseases of the respiratory system ,Middle Aged ,medicine.disease ,Intrinsic PEEP ,Forced oscillation technique ,030228 respiratory system ,Exhalation ,Chronic Disease ,Breathing ,Cardiology ,Non-invasive ventilation ,Female ,medicine.symptom ,business - Abstract
Background Tidal expiratory flow limitation (EFLT) promotes intrinsic PEEP (PEEPi) in patients with chronic obstructive pulmonary disease (COPD). Applying non-invasive ventilation (NIV) with an expiratory positive airway pressure (EPAP) matching PEEPi improves gas exchange, reduces work of breathing and ineffective efforts. We aimed to evaluate the effects of a novel NIV mode that continuously adjusts EPAP to the minimum level that abolishes EFLT. Methods This prospective, cross-over, open-label study randomized patients to one night of fixed-EPAP and one night of EFLT-abolishing-EPAP. The primary outcome was transcutaneous carbon dioxide pressure (PtcCO2). Secondary outcomes were: peripheral oxygen saturation (SpO2), frequency of ineffective efforts, breathing patterns and oscillatory mechanics. Results We screened 36 patients and included 12 in the analysis (age 72 ± 8 years, FEV1 38 ± 14%Pred). The median EPAP did not differ between the EFLT-abolishing-EPAP and the fixed-EPAP night (median (IQR) = 7.0 (6.0, 8.8) cmH2O during night vs 7.5 (6.5, 10.5) cmH2O, p = 0.365). We found no differences in mean PtcCO2 (44.9 (41.6, 57.2) mmHg vs 54.5 (51.1, 59.0), p = 0.365), the percentage of night time with PtcCO2 > 45 mm Hg was lower (62(8,100)% vs 98(94,100)%, p = 0.031) and ineffective efforts were fewer (126(93,205) vs 261(205,351) events/hour, p = 0.003) during the EFLT-abolishing-EPAP than during the fixed-EPAP night. We found no differences in oxygen saturation and lung mechanics between nights. Conclusion An adaptive ventilation mode targeted to abolish EFLT has the potential to reduce hypercapnia and ineffective efforts in stable COPD patients receiving nocturnal NIV. Trial registration: ClicalTrials.gov, NCT04497090. Registered 29 July 2020—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04497090.
- Published
- 2020